DCM
RCUS icon

Driehaus Capital Management’s Arcus Biosciences RCUS Stock Holding History

Driehaus Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25,000
Closed -$347K – 456
2020
Q1 		$347K Buy
+25,000
New +$311K 0.01% 325
2018
Q2 		– Sell
-50,150
Closed -$774K – 551
2018
Q1 		$774K Buy
+50,150
New +$835K 0.03% 366

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Driehaus Capital Management's RCUS Position: Q2 2020 in Review

Driehaus Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2020, closing a stake of 25,000 shares — an estimated $347K sold.

Driehaus Capital Management first reported a position in RCUS in Q1 2018 and held it in 2 quarters. The position peaked at $774K in Q1 2018. 139 funds tracked by Wall St. Rank hold RCUS as of Q2 2020.

  • Driehaus Capital Management reported no remaining Arcus Biosciences position as of Q2 2020 after selling out during the quarter.
  • Driehaus Capital Management sold 25,000 Arcus Biosciences shares in Q2 2020, an estimated $347K.
  • Driehaus Capital Management first reported a position in Arcus Biosciences in Q1 2018 and held it in 2 quarters.
  • Driehaus Capital Management's Arcus Biosciences position peaked at $774K in Q1 2018.
  • 139 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2020.

Based on Driehaus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.